Dr. Michael J. Morris on Radium-223 Combination Options for mCRPC

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses the benefits of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 is a first-in-class radiopharmaceutical; there is really nothing else like it, says Morris.

Its mechanism of action results in a very low toxicity profile, says Morris. It has very low homological toxicities, and it prolongs life and delays skeletal-related events. It has a lot of potential to be combined with other agents, says Morris.

It is being combined in clinical trials right now with AR-directed therapies. Early studies are also moving forward combining radium-223 with chemotherapy. It cannot be combined with chemotherapy currently, but safety data is forthcoming, says Morris.

It is also being investigated in combination with tumor-directed therapy.